Navigation Links
Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
Date:3/24/2011

nd efficacy of calcitonin with the advantage of once-daily oral administration to the millions of postmenopausal women with osteoporosis.  We believe that our product has the potential to be the first FDA-approved oral formulation of calcitonin to reach the market."  

Separately, Tarsa announced that it has completed screening and has begun to randomize patients in its Phase II osteoporosis prevention trial.  TAR01-201 is a double-blind study comparing Tarsa's oral recombinant salmon calcitonin to placebo in approximately 120 postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.  This proof-of-concept study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population.  This trial, conducted entirely in the US, is expected to complete enrollment by the end of April 2011.

Dr. David Krause, Chief Medical Officer of Tarsa, commented, "Calcitonin has a long history of safety and efficacy as an osteoporosis therapy, and we believe that the availability of Tarsa's easy-to-use, once-daily oral calcitonin tablet would be welcomed by many healthcare providers and patients who are seeking additional osteoporosis treatment and prevention options, especially in view of continuing concerns about potential long-term safety issues with some other popular classes of osteoporosis drugs."

Calcitonin is approved for the treatment and prevention of postmenopausal osteoporosis, but its use has been limited by the fact that it is currently available only in intranasal and injectable forms.  Tarsa's oral calcitonin product has been shown in prior clinical studies to deliver the desired blood levels of calcitonin and reduce levels of biomarkers of bone resorption.  

For more information about the ORACAL osteoporosis treatment trial and the TAR01-201 osteoporosis prevention trial, visit

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Ill., Oct. 31, 2014  AbbVie (NYSE: ... the third quarter ended Sept. 30, 2014. ... performance of our business with double-digit growth from ... business grew nearly 14 percent in the quarter ... chief executive officer, AbbVie.  "We exceeded our outlook ...
(Date:10/30/2014)... 2014 Stryker Orthopaedics, the Official Joint Replacement ... rounding out its debut year of the relationship at ... AZ. This marks the eleventh tournament stop ... the brand has activated on-site with the "Stryker Mobility ... on the importance of joint health.  ...
(Date:10/30/2014)...  Zimmer Holdings, Inc. (NYSE: ZMH ... team and organizational structure of the combined company following ... that the combined organization will leverage the strength of ... with the new brand to be rolled out across ... The future leadership team is committed to establishing Zimmer ...
Breaking Medicine Technology:AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing ... autoimmune diseases, today announced that its Senior Vice President and ... Annual BIO Investor Forum on October 29, 2009 in San ... available on the company,s website at www.micromet-inc.com ...
... Incorporated (Nasdaq: ARAY ), a global leader in ... an America,s region thereby establishing regionalized management and operational ... formation of this new Americas region, along with the ... each region control of revenue and profitability and responsibility ...
Cached Medicine Technology:Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009 2Accuray Announces Regionalized Management Strategy for Americas 2Accuray Announces Regionalized Management Strategy for Americas 3
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... York, NY (PRWEB) October 31, 2014 ... one of the most remarkable gifts of life — ... platform for matching extraordinary surrogate mothers and donors with ... about individuals in unforeseen circumstances. , It’s a collective ... donors, surrogacy agencies, surrogacy lawyers, and fertility clinics that ...
(Date:10/31/2014)... Triple Board Certified surgeon Dr. Jeffrey ... transform the appearance of military veteran Joseph Jones. ... Plastic and Reconstruction Surgery (AAFPRS) Faces of Honor program, ... hair Jones lost during an IED blast almost ten ... procedure, valued around $16,000, took Dr. Epstein over eight ...
(Date:10/31/2014)... October 31, 2014 BCC Research ( http://www.bccresearch.com ... AIR QUALITY MARKET , the U.S. indoor air quality (IAQ) ... with a compound annual growth rate (CAGR) of 7% over ... to grow at a CAGR of 7.4%. , Since ... toxic mold, the outbreak of infectious diseases such as bird ...
(Date:10/31/2014)... 2014 Radiology and EMR Integration ... difference between diagnostic imaging centers but Connectivity is ... DigitalOne. “Differentiation is critical in all businesses ... you consider the intense competition and the downward ... will stand-out from the competition by fully integrating ...
Breaking Medicine News(10 mins):Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... (Dec. 20, 2007) -- Using new approaches, an interdisciplinary ... in New York City has gained a view of ... difficulty in patients with borderline personality disorder -- shedding ... early days yet, but the work is pinpointing functional ...
... More Benefit Online Nurse Community, SAN DIEGO, ... professionals to connect with their peers are growing ... site rising to the top,designed exclusively for nursing ... with their peers. NurseConnect, (http://www.nurseconnect.com ) is a ...
... 21 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... application (sNDA) with the U.S. Food and Drug,Administration ... with,previously untreated multiple myeloma (MM). The filing is ... VISTA(1) trial, one of the largest,international, randomized clinical ...
... MURRYSVILLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RESP ... merger,agreement pursuant to which Royal Philips Electronics (AEX: PHI, ... all of the outstanding,shares of Respironics for USD 66.00 ... approximately USD 5.1 billion. The offer price represents a,premium ...
... Upon an ex parte motion,by the Service Employees ... (TRO) was issued late on Thursday, December 20,by ... Michigan,enjoining the Michigan Department of Community Health, Manor ... Group from taking certain actions related to,completing the ...
Cached Medicine News:Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 3Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 4Health News:Professional Networking Web Site, NurseConnect.com Launches Innovative Features 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 3Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 4Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 5Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Manor Care To Vigorously Contest TRO 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: